Prevention of Akute Kidney Injury, Hearttransplant, ANP

• Status: Recruiting
• Trial end date: 2022-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Prospective, blinded, placebo-controlled trial. Patients: Adult patients (>18 years of age) undergoing de novo Htx, with a preoperative GFR > 30ml/min, not receiving an ABO-incompatible organ with an ischemia time of > 6 hours. A donor age > 70 years is an exclusion criteria.

Intervention: Infusion of h-ANP fore five days, starting at the induction of anesthesia.

Outcome: Kidney function, evaluated with serum creatinine day 1-7 and kidney clearance, 4-5 Days after Htx plus after 3 and 12 months.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Sahlgrenska University Hospital, Sweden

Criteria

Inclusion Criteria:

• De novo Htx.

• Preoperative GFR > 30ml/min/1,73m2.

• >18 years old.

• Written consent.

Exclusion Criteria:

• Multi organ transplantation or previous heart transplant.

• ECMO

• Donor age > 70 years.

• Dialysis.

• ABO-incompatible organ.

• Donor heart ischemia time > 6 tim.

• Known kidney disease.

• Other planed study within 2 mounth.